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Background 
The proportion of older (aged 
≥50 years) people living with human 
immunodeficiency virus (PLHIV) 
within the HIV-positive population 
is increasing. Many comorbidities 
associated with ageing are observed 
more frequently and/or occur at an 
earlier age among PLHIV, compared 
with people who are uninfected.
Objective
The aim of this article is to improve the 
confidence of treating physicians who 
have limited HIV experience in providing 
care for the increasingly elderly HIV 
population by presenting a contemporary 
clinical picture of older PLHIV and 
discussing the key evidence-based 
principles of management, with 
reference to data in the Australian 
setting where applicable.
Discussion
Older PLHIV, in particular those with 
complex comorbidities, are likely to 
benefit from comprehensive 
multidisciplinary medical and 
psychosocial support as they age. 
Physicians are well placed to diagnose 
and treat HIV as early as possible in 
older people and ensure counselling to 
prevent secondary transmission of HIV.
PROJECTIONS INDICATE that the 
proportion of people living with human 
immunodeficiency virus (PLHIV) 
aged ≥50 years is increasing and will 
continue to increase for at least the next 
decade in Western countries.1,2 Many 
comorbidities associated with ageing, such 
as cardiovascular disease, osteoporosis, 
malignancy, metabolic disorders and renal 
disease, occur more frequently and/or 
at an earlier age in PLHIV than in people 
who are uninfected.3–5 Treating physicians 
with limited HIV experience are generally 
expert in early identification, prevention 
and management of age-associated 
comorbidities in the general population, 
and are therefore well placed to manage 
and care for older PLHIV. 
HIV prevalence in older people
In 2017 there were an estimated 27,545 
PLHIV, including a total of 963 cases of 
newly diagnosed HIV, in Australia.6 The 
majority were in the exposure category 
of men who have sex with men (MSM) 
at the time of diagnosis.6 At present, 
approximately 46% of PLHIV in Australia 
are aged ≥50 years.6 An increase in 
diagnoses in older people, as well as an 
increase in the life expectancy of PLHIV 
taking antiretroviral therapy (ART), are 
contributing to an increasingly aged 
population of PLHIV and consequently 
a unique presentation of age-related 
comorbidities that require clinical 
management.7,8
Age-related comorbidities in 
older people living with HIV
PLHIV have an increased risk of 
age-associated comorbidities, compared 
with individuals of the same age in the 
general population.2–4 Factors associated 
with these comorbidities in PLHIV include 
a lower nadir CD4 cell count, prolonged 
ART exposure, persistent inflammation 
secondary to chronic viral activation 
and various lifestyle risk factors.3,9 A 
decreased immunological response due 
to increasing age in PLHIV can also occur; 
this typically manifests as a poor response 
to vaccination, an increased susceptibility 
to infection and/or an increased risk 
of other comorbidities.10,11 In addition, 
older people with a long history of 
ART may have medication-associated 
morbidities from older or experimental 
agents used in the past.12 Neurocognitive 
conditions associated with HIV, 
including HIV-associated dementia 
and HIV-associated neurocognitive 
impairment, are of particular ongoing 
concern as little is known regarding their 
progression and management, and they 
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may result in sub-optimal adherence to 
treatment and treatment failure. Some 
cancers have a risk of earlier onset in 
PLHIV and, while the incidence of Kaposi 
sarcoma and non-Hodgkin lymphoma 
is decreasing for PLHIV, the risk of anal, 
liver and colorectal cancer is increasing.13 
The key characteristics of comorbidities 
commonly associated with ageing in 
PLHIV compared with people who are 
uninfected are summarised in Table 1. 
Multimorbidity, which commonly 
refers to the coexistence of two or more 
clinically manifest chronic diseases,14 
is also more prevalent in PLHIV than in 
people who are uninfected.15,16 Some older 
PLHIV are newly diagnosed, whereas 
others have lived with HIV for a long time 
and may have been treated long term 
with ART and/or previously diagnosed 
with one or more acquired immune 
deficiency syndrome (AIDS)-defining 
conditions. This is important to note, as 
older people with a longer duration of 
HIV infection have a higher probability 
of multimorbidity than PLHIV who 
seroconvert at older ages.15 Therefore, 
similar to people who are uninfected, 
the development of age-related 
comorbidities and multimorbidity for 
PLHIV likely involve heterogeneous 
processes. Multimorbidity is of particular 
concern as it can contribute to frailty 
and therefore add to vulnerability and 
complexity in clinical management.4,16 
In fact, emerging evidence indicates that 
assessment of PLHIV using a frailty index 
can predict survival and multimorbidity,17 
highlighting the potential negative 
consequences of frailty in older PLHIV.
Clinical management of 
older people living with HIV
ART is recommended for all PLHIV, 
including older people, and early treatment 
initiation is particularly important for older 
people because of their potentially blunted 
response to ART and increased risk of 
serious non-AIDS events.18 ART suppresses 
plasma viraemia, which decreases the risk 
of drug-resistant mutations, preserves or 
improves CD4 cell numbers and confers 
considerable morbidity and mortality 
benefits. As a result, life-expectancy in 
people with HIV is now approaching that 
of the general population.19 
However, some ART medications can 
also exacerbate age-related comorbidities 
(Table 2). As a consequence of these 
potential toxicities, it is important to 
employ a proactive approach to ART 
management in older PLHIV. ART choice 
should ideally be based on management 
of comorbidities, multimorbidity, 
Table 1. Age-related comorbidities in people living with HIV
Comorbidities
Acute myocardial infarction • Up to 50% increased risk of acute myocardial infarction33
• Leading cause of death in PLHIV on effective ART33
Bone disease • Six-fold increase in low BMD34
• Four-fold increase in osteoporosis risk35
End-stage liver disease • Progression to end-stage liver disease more rapid with 
HBV/HIV coinfection than with HBV monoinfection18
• Three-fold greater risk of decompensated liver disease 
with HCV/HIV coinfection than with HCV monoinfection18
End-stage renal disease • Earlier diagnosis of end-stage renal disease5
• TDF and other comorbidities can increase risk11
HAND • More than 50% of PLHIV have some neurocognitive 
impairment36
• 2–8% of PLHIV have HIV-associated dementia37
• HAND and HIV-associated dementia may contribute to 
treatment failures
Mental health conditions • 20–40% of PLHIV compared with 7% of the general 
population report depression28
Non–AIDS defining cancer • Increased risk of lung, anal and liver cancer and Hodgkin 
lymphoma13 
• Melanoma is common in Australian PLHIV38
Type 2 diabetes mellitus • 4% higher prevalence39
• More likely to develop at younger ages and in the absence 
of obesity39
• Increasing age, HCV coinfection and increasing BMI have 
a more pronounced effect on the risk of type 2 diabetes 
mellitus40
Geriatric syndromes
Delirium • Delirium can occur in young adults and children 
with HIV41,42 
Falls • Fall rate increased in PLHIV43 
Frailty • Increased risk of pre-frailty and frailty32,44 
• Occurs in 11–23% of Australian PLHIV32 
Functional impairment and 
disability 
• Increased risk of functional impairment and disability, 
including difficulty with mobility, self-care and activities 
of daily living45
Hearing and visual loss • Poorer lower-frequency and higher-frequency hearing46
• Vision function abnormalities are common in people 
with AIDS47
Urinary incontinence • Increased incidence of urinary continence in PLHIV48
AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; BMD, bone mineral density; 
BMI, body mass index; HIV, human immunodeficiency virus; HAND, HIV-associated neurocognitive 
impairment; HBV, hepatitis B virus; HCV, hepatitis C virus; NADC, non–AIDS defining cancer; 
PLHIV, people living with HIV; TDF, tenofovir disoproxil fumarate
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polypharmacy and frailty, in addition 
to virological suppression. A complete 
treatment history is important, and 
HIV section 100 prescribers should 
be consulted to review ART regimens 
and, if clinically appropriate, modify 
regimens to include safer agents as part 
of the management of comorbidities. 
For example, changing from a regimen 
containing tenofovir disoproxil fumarate 
to a regimen containing tenofovir 
alafenamide can result in significant 
improvements in glomerular function and 
spine and hip bone mineral densities.20 
Changing to a two-medication regimen, 
such as dolutegravir/rilpivirine,21–23 is 
another possible treatment strategy 
that may be used to avoid toxicities, 
although any decision to simplify a 
treatment regimen should be considered 
in consultation with an HIV section 100 
prescriber.
ART regimens with a high genetic 
barrier to resistance, such as those 
containing an agent from the integrase 
inhibitor class, for example dolutegravir 
or bictegravir,24–26 or protease inhibitor 
class, are particularly important for 
older PLHIV. 
Evidence-based approaches to 
management of common individual 
comorbidities in PLHIV are summarised 
in Table 3. PLHIV benefit from the same 
age-appropriate health assessments as 
those for the general population. The 
Royal Australian College of General 
Practitioners’ Guidelines for preventive 
activities in general practice, 9th edition 
(www.racgp.org.au/your-practice/
guidelines/redbook) is therefore an 
appropriate guide when manageing older 
PLHIV, in particular when screening for 
bowel, skin and anal cancer. Anal cancer in 
MSM is a particularly important issue, and 
an Australian study has shown that regular 
digital anorectal examinations for MSM 
aged ≥50 years is cost effective and may 
detect anal cancer earlier.27 The Australian 
Society for HIV, Viral Hepatitis and Sexual 
Health Medicine (ASHM) also offers 
helpful resources for HIV management, 
including specific recommendations for 
older PLHIV (www.ashm.org.au/HIV/
hiv-management).
Screening for comorbidities should 
ideally include the collection of modifiable 
and non-modifiable risk factors, estimation 
of risk probability using appropriate 
algorithms and evaluation using markers of 
subclinical disease. Furthermore, duration 
of ART should be taken into account when 
considering surveillance of disease risk, 
frequency of follow-up, intensity of care 
and choice of therapy.15 
When manageing comorbidities 
in older PLHIV, it is important that 
patients adhere to ART so that HIV viral 
load remains undetectable. Physicians 
are well placed to treat risk factors for 
existing comorbidities and empower 
PLHIV to make lifestyle changes.28 
The benefits of ceasing use of tobacco, 
alcohol and other drugs should either be 
delivered repeatedly where appropriate, 
or continued abstinence encouraged.28 
Adherence to ART should also be 
assessed, ideally every three to six 
months, and factors that may decrease 
adherence, such as complicated regimens, 
unnecessary concomitant medications 
and neurocognitive deficits, should be 
identified and managed.28
Polypharmacy is particularly common 
in older PLHIV,18 leading to a greater 
risk of drug–drug interactions (DDIs) 
between ART agents and concomitant 
medications; consequently, there is an 
increased risk of non-adherence, cognitive 
impairment, impaired balance, falls and 
hospitalisation.28 It is important that 
physicians periodically review the potential 
for DDIs with ART, particularly when 
starting or changing concomitant non-HIV 
medications.18 Furthermore, physicians  
should routinely check for potentially 
inappropriate medication prescriptions, 
particularly in older PLHIV. The University 
of Liverpool HIV drug interaction 
checker (www.hiv-druginteractions.org) 
is a particularly useful tool to assess the 
potential for DDIs.29 A recent Australian 
study showed that medication reviews 
by HIV specialist pharmacists within the 
general practice setting may help identify, 
prevent and/or resolve DDIs and other 
medication-related problems in PLHIV.30
The future of HIV care: A 
multidimensional approach
Frailty can predispose individuals to 
increased risks of multimorbidity and 
mortality.11 HIV infection increases 
Table 2. Selected age-related comorbidities that may be exacerbated by, or 
associated with, antiretroviral agents
Comorbidity Antiretroviral agent effects
Bone disease • Tenofovir disoproxil fumarate: low BMD and 
osteoporotic fracture49
Cardiovascular disease • Abacavir: MI50
• Darunavir:* CVD51
Diabetes mellitus • Zidovudine, stavudine, didanosine, lopinavir, 
nelfinavir and indinavir52
Neurocognitive impairment • Efavirenz: nervous system side effects and impaired 
neurocognitive functioning53
• Dolutegravir: neuropsychiatric side effects including 
insomnia and sleep disturbance54
Renal disease • Adefovir:† proximal renal tubular dysfunction55
• Atazanavir: kidney stones56
• Indinavir: CKD and renal stones57,58
• Tenofovir disoproxil fumarate: CKD59
*While darunavir has been shown to be associated with increased CVD risk, atazanavir has not, 
suggesting that protease inhibitors as a class may not be associated with an increased CVD risk. 
†Adefovir was used during HIV clinical trials in Australia but rarely outside of the clinical trial setting.
BMD, bone mineral density; CKD, chronic kidney disease; CVD, cardiovascular disease; HIV, human 
immunodeficiency virus; MI, myocardial infarction
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frailty risk,31 and a recent study estimated 
frailty to occur in 11–23% of PLHIV in 
one Australian cohort.32 It is particularly 
important to identify and manage frailty 
because frailty can lead to or exacerbate 
disability. While frailty can be reversed, 
disability cannot. However, a lack of 
consensus remains on the defining criteria 
for diagnosis of frailty, and treatment of 
frailty can be complex, with no evidence-
based strategies yet developed.31 
To effectively manage ageing as a 
whole, the future of  care for PLHIV 
will likely require a shift from the 
traditional interdisciplinary approach 
to a comprehensive ‘geriatric-type’ 
multidimensional, multidisciplinary 
assessment aimed at evaluating a 
combination of medical, psychosocial and 
functional capabilities and limitations.28 
Diverse consultation approaches that are 
built into individualised management 
plans, and focus on quality of life and 
prevention of disability, are likely to be 
of benefit. The increasing proportion of 
older PLHIV who have comorbidities, 
multimorbidity and/or frailty also suggests 
an evolving geriatric-HIV scenario in which 
evidence-based screening, monitoring and 
treatment guidelines will almost certainly 
be of value to ensure high-quality care.
In the meantime, current guidelines 
recommend that HIV experts, primary 
care providers and other specialists 
work together to optimise care for older 
PLHIV, particularly those with complex 
comorbidities.18 Early HIV diagnosis in 
older people can be facilitated by enquiring 
in a non-judgemental manner about 
risk factors for HIV, including sexual 
history and intravenous drug use, and 
regularly testing those at risk. Counselling 
remains important to prevent secondary 
transmission of HIV. Older people are 
also likely to benefit from comprehensive 
multidisciplinary medical and psychosocial 
support to help them age as successfully as 
possible with HIV.
Conclusions
As a result of the ageing HIV population, 
comorbidities, multimorbidity and 
frailty will increasingly become a major 
focus of care. Continued research into 
ageing in older PLHIV is required for the 
management, and perhaps prevention, of 
comorbidities, multimorbidity and frailty, 
and may form the basis of a new model 
for manageing ageing in the general 
population.
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Table 3. Overview of key aspects to management of common individual comorbidities in older people living with HIV*
Comorbidity Key management aspects
Bone disease • Consider DEXA† for those with risk factors28
• Address fall risk and ensure sufficient dietary calcium and vitamin D28
• Refer complicated cases to an osteoporosis specialist28
• Replace TDF with TAF18 ‡§
Cardiovascular disease • Assess risk with D:A:D score60 or Framingham score every 2 years in all men aged >40 years and 
women aged >50 years without CVD28
• Use ABC with caution in cases of high CVD risk (>20%)18 ‡§
• Reduce all modifiable risk factors, particularly blood pressure, glucose and lipids28
• Encourage lifestyle modification, particularly smoking cessation28
Neurocognitive impairment • Neuropsychological evaluation28
• Neurological examination, brain MRI and CSF examination28
• Address adverse lifestyle habits and encourage adherence to ART if needed28
• Avoid EFV, particularly in patients with mental illness28 ‡§
Renal disease • Annual assessment for risk factors of CKD, or more frequently as indicated28 II
• Adjust ART dose or modify ART regimen28 ‡§
• Replace TDF with TAF28 ‡§
• Refer to nephrologist if new CKD or progressive decline in eGFR28
*This table summarises the management of individual comorbidities only, and not aging, which includes multimorbidity, frailty and disability. While there is a 
plethora of evidence-based guidance for the management of individual comorbidities in HIV, little is currently known about achievement of successful ageing with 
HIV, which consequently remains major clinical challenge.
†DEXA is not funded for all patients by the Medicare Benefits Schedule in Australia.
‡To avoid drug–drug interactions with HIV medications, always consult the University of Liverpool HIV drug interaction checker before prescribing new 
medications (www.hiv-druginteractions.org)
§In Australia, refer to an HIV section 100 prescriber to review and reactively or pre-emptively switch ART when appropriate.
II More frequent monitoring is required if eGFR <90 mL/min, CKD risk factors present and/or prior to starting and treatment with nephrotoxic drugs. 
ABC, abacavir; ART, antiretroviral therapy; CKD, chronic kidney disease; CSF, cerebrospinal fluid; CVD, cardiovascular disease; D:A:D, data collection on adverse 
events of anti-HIV drugs; DEXA, dual-energy X-ray absorptiometry; eGFR, estimated glomerular filtration rate; EFV, efavirenz; MRI, magnetic resonance imaging; 
TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate
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